A TNFR2 biparatopic antagonist reverses immune suppression through a crosslinking-resistant and ADCC- independent mechanism
Clicks: 1
ID: 318630
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #82 of 88 articles by views in journal of leukocyte biology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Tumor necrosis factor receptor 2 (TNFR2) is a promising immunotherapeutic target due to its high upregulation on immunosuppressive populations, like regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). The clinical efficacy of conventional bivalent TNFR2 antagonists, such as BI1808, is fundamentally constrained by a heavy reliance on Fc-mediated effector functions and a significant risk of ‘agonistic conversion’ upon crosslinking within the tumor microenvironment. To overcome these liabilities, we engineered Duo1, a novel biparatopic antagonist that enables simultaneous, monovalent engagement of two distinct TNFR2 epitopes. Biophysical analysis confirmed Duo1 forms stable 1:1 complexes with TNFR2 with high-affinity (KD = 0.165 nM), structurally locking the target to prevent the receptor oligomerization required for agonistic signaling. Crucially, while conventional bivalent frameworks convert into potent agonists upon cross-linking, Duo1 maintains absolute, durable antagonism regardless of FcγR engagement. Functionally, Duo1 potently suppressed Treg differentiation and reversed Treg-mediated immunosuppression in vitro without impairing CD8+ effector T cell or CD4+ conventional T cell function.. In a TNFR2-humanized MC38 syngeneic model, Duo1 mediated significant, dose-dependent tumor growth inhibition comparable to benchmark BI1808. Notably, this anti-tumor efficacy was fully preserved in an effector-silent (PGLALA) variant, confirming that its therapeutic mechanism operates through pure antagonistic signaling blockade, independent of Fc-mediated effector functions. Furthermore, treatment with Duo1 significantly remodeled the tumor microenvironment, markedly reducing immunosuppressive populations and increasing the intratumoral CD8+/Treg ratio. By uncoupling anti-tumor activity from both the risks of cross-linking induced agonistic conversion and a dependence on immune cell mediated effector function, Duo1 represents a highly superior next-generation immunotherapeutic paradigm for TNFR2-rich, immunosuppressive malignancies.
| Reference Key |
openalex_W7165801087
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Shusu Liu, Zhichao Ai, Jinli Xie, Kai Yu, Fei Chen, Zhongzhou Zheng, Yijie Gao, Zhipeng Yan |
| Journal | journal of leukocyte biology |
| Year | 2026 |
| DOI |
10.1093/jleuko/qiag086
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.